Dr. Sharman on Entospletinib in Patients With CLL

Jeff Sharman, MD
Published: Friday, Dec 18, 2015



Jeff Sharman, MD, director of Research with Willamette Valley Cancer Institute and Research Center, medical director of Hematology Research for The US Oncology Network, discusses clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.

Entospletinib is a SYK inhibitor, Sharman explains. SYK is one member of the downstream signaling pathway of the B-cell receptor, in which other targets include BTK and PI3K delta. Agents such as ibrutinib and idelalisib are already used in this space, but this third agent targets another portion of the pathway, he adds.

Substantial activity with entospletinib has been observed in patients in an ongoing study. High levels of response and prolonged disease control have also been demonstrated. Reported toxicities, which include liver function test abnormalities, have been manageable, Sharman says.



Jeff Sharman, MD, director of Research with Willamette Valley Cancer Institute and Research Center, medical director of Hematology Research for The US Oncology Network, discusses clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.

Entospletinib is a SYK inhibitor, Sharman explains. SYK is one member of the downstream signaling pathway of the B-cell receptor, in which other targets include BTK and PI3K delta. Agents such as ibrutinib and idelalisib are already used in this space, but this third agent targets another portion of the pathway, he adds.

Substantial activity with entospletinib has been observed in patients in an ongoing study. High levels of response and prolonged disease control have also been demonstrated. Reported toxicities, which include liver function test abnormalities, have been manageable, Sharman says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x